Cargando…

JAK/STAT blockade reverses the malignant phenotype of Hodgkin and Reed-Sternberg cells

Constitutive activation of the JAK/STAT pathway is a common phenomenon in classic Hodgkin lymphoma (cHL). The clinical potential of anti-JAK/STAT therapy is being explored in early-stage clinical trials. Notwithstanding, very little information is available about the complex biological consequences...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fernández, Sara, Solórzano, Jose L., Díaz, Eva, Menéndez, Victoria, Maestre, Lorena, Palacios, Sara, López, Mar, Colmenero, Argentina, Estévez, Mónica, Montalbán, Carlos, Martínez, Ángel, Roncador, Giovanna, García, Juan F.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The American Society of Hematology 2022
Materias:	Lymphoid Neoplasia
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10407154/ https://www.ncbi.nlm.nih.gov/pubmed/36459489 http://dx.doi.org/10.1182/bloodadvances.2021006336

Ejemplares similares

Combination brentuximab vedotin and bendamustine for pediatric patients with relapsed/refractory Hodgkin lymphoma
por: Forlenza, Christopher J., et al.
Publicado: (2021)

Therapy Selection for Hodgkin Lymphoma in Sickle Cell Disease: balancing risks and benefits
por: Fraley, Claire E., et al.
Publicado: (2022)

Checkpoint protein expression in the tumor microenvironment defines the outcome of classical Hodgkin lymphoma patients
por: Karihtala, Kristiina, et al.
Publicado: (2022)

Brentuximab vedotin after autologous transplantation in pediatric patients with relapsed/refractory Hodgkin lymphoma
por: Forlenza, Christopher J., et al.
Publicado: (2023)

A significant proportion of classic Hodgkin lymphoma recurrences represents clonally unrelated second primary lymphoma
por: van Bladel, Diede A. G., et al.
Publicado: (2023)

Brentuximab vedotin plus AVD for Hodgkin lymphoma: incidence and management of peripheral neuropathy in a multisite cohort
por: Bowers, Jackson T., et al.
Publicado: (2023)

Informing radiotherapy decisions in stage I/IIa Hodgkin lymphoma: modeling life expectancy using radiation dosimetry
por: Jones, David A., et al.
Publicado: (2022)

International validation of a health-related quality-of-life questionnaire for Hodgkin lymphoma: the EORTC QLQ-HL27
por: Oerlemans, Simone, et al.
Publicado: (2023)

Blockade of CCR1 induces a phenotypic shift in macrophages and triggers a favorable antilymphoma activity
por: Le, Kang, et al.
Publicado: (2023)

Incidence and time trends of second primary malignancies after non-Hodgkin lymphoma: a Swedish population-based study
por: Joelsson, Joel, et al.
Publicado: (2022)

Low incidence of invasive fungal disease following CD19 chimeric antigen receptor T-cell therapy for non-Hodgkin lymphoma
por: Little, Jessica S., et al.
Publicado: (2022)

Prognostic model using (18)F-FDG PET radiomics predicts progression-free survival in relapsed/refractory Hodgkin lymphoma
por: Driessen, Julia, et al.
Publicado: (2023)

SBNO2 is a critical mediator of STAT3-driven hematological malignancies
por: Brandstoetter, Tania, et al.
Publicado: (2023)

The location of the t(4;14) translocation breakpoint within the NSD2 gene identifies a subset of patients with high-risk NDMM
por: Stong, Nicholas, et al.
Publicado: (2023)

Hodgkin Reed–Sternberg-Like Cells in Non-Hodgkin Lymphoma
por: Parente, Paola, et al.
Publicado: (2020)

Whole-genome analysis identifies novel drivers and high-risk double-hit events in relapsed/refractory myeloma
por: Ansari-Pour, Naser, et al.
Publicado: (2023)

Loss of COP9 signalosome genes at 2q37 is associated with IMiD resistance in multiple myeloma
por: Gooding, Sarah, et al.
Publicado: (2022)

New molecular targets in Hodgkin and Reed-Sternberg cells
por: Sadaf, Hummaira, et al.
Publicado: (2023)

Soluble CD163 predicts outcome in both chemoimmunotherapy and targeted therapy–treated mantle cell lymphoma
por: Nikkarinen, Anna, et al.
Publicado: (2023)

Sézary syndrome patient–derived models allow drug selection for personalized therapy
por: Gallardo, Fernando, et al.
Publicado: (2022)

Gene expression profiling and FDG-PET radiomics uncover radiometabolic signatures associated with outcome in DLBCL
por: Mazzara, Saveria, et al.
Publicado: (2022)

High-sensitivity next-generation sequencing MRD assessment in ALL identifies patients at very low risk of relapse
por: Short, Nicholas J., et al.
Publicado: (2022)

High-risk subtypes of chronic lymphocytic leukemia are detectable as early as 16 years prior to diagnosis
por: Kolijn, P. Martijn, et al.
Publicado: (2022)

Genomic analyses of microdissected Hodgkin and Reed-Sternberg cells: mutations in epigenetic regulators and p53 are frequent in refractory classic Hodgkin lymphoma
por: Mata, Elena, et al.
Publicado: (2019)

Candidate germline biomarkers of lenalidomide efficacy in mantle cell lymphoma: the Fondazione Italiana Linfomi MCL0208 trial
por: Ferrero, Simone, et al.
Publicado: (2023)

Peripheral T-cell lymphoma: molecular profiling recognizes subclasses and identifies prognostic markers
por: Rodríguez, Marta, et al.
Publicado: (2021)

p53 expression in Reed-Sternberg cells of Hodgkin's disease.
por: Gupta, R. K., et al.
Publicado: (1992)

SNP rs6457327 in the HLA region on chromosome 6p is predictive of the transformation of follicular lymphoma
por: Wrench, David, et al.
Publicado: (2011)

Poor neutralizing antibody responses in 106 patients with WM after vaccination against SARS-CoV-2: a prospective study
por: Gavriatopoulou, Maria, et al.
Publicado: (2021)

Overexpression of wild-type IL-7Rα promotes T-cell acute lymphoblastic leukemia/lymphoma
por: Silva, Ana, et al.
Publicado: (2021)

Oral ixazomib, lenalidomide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma
por: Facon, Thierry, et al.
Publicado: (2021)

Venetoclax sensitivity in multiple myeloma is associated with B-cell gene expression
por: Gupta, Vikas A., et al.
Publicado: (2021)

COVID-19 in patients with CLL: how can we change the odds?
por: Herishanu, Yair, et al.
Publicado: (2021)

The microenvironment of DLBCL is characterized by noncanonical macrophages recruited by tumor-derived CCL5
por: Manfroi, Benoît, et al.
Publicado: (2021)

Nras(Q61R/+) and Kras(−/−) cooperate to downregulate Rasgrp1 and promote lympho-myeloid leukemia in early T-cell precursors
por: Wen, Zhi, et al.
Publicado: (2021)

Toward prevention of childhood ALL by early-life immune training
por: Hauer, Julia, et al.
Publicado: (2021)

Activated natural killer cells predict poor clinical prognosis in high-risk B- and T-cell acute lymphoblastic leukemia
por: Duault, Caroline, et al.
Publicado: (2021)

Association of allele-specific methylation of the ASNS gene with asparaginase sensitivity and prognosis in T-ALL
por: Akahane, Koshi, et al.
Publicado: (2022)

Asparaginase enzyme activity levels and toxicity in childhood acute lymphoblastic leukemia: a NOPHO ALL2008 study
por: Lynggaard, Line Stensig, et al.
Publicado: (2022)

Determination of MYD88(L265P) mutation fraction in IgM monoclonal gammopathies
por: Bagratuni, Tina, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_3c4iim28lkoitg3ernqgu4tgoq